Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
ketamine

Naltrexone in the Treatment of Ketamine Use Disorders: A Case Report and Literature Review (Verma, et al, 2025)

"findings consistent w/ 2 prior reports - use of naltrexone in KUDs at the dosage of 50 mg/day successfully helped patients achieve abstinence... naltrexone reduces antidepressant effects of ketamine, indicating overlap between opioid system & ketamine's NMDA receptor activity. "
Michael DeMarco, PhD

by Michael DeMarco, PhD

Naltrexone in the Treatment of Ketamine Use Disorders: A Case Report and Literature Review - PubMed
Our findings are consistent with 2 prior reports that have highlighted the use of naltrexone in KUDs. The 2 previous case reports indicated that naltrexone at the dosage of 50 mg/day successfully helped the patients to achieve abstinence. Studies have shown that naltrexone reduces the antidepressant …
PubMedRishi Verma

(2025):"Our findings are consistent with 2 prior reports that have highlighted the use of naltrexone in KUDs. The 2 previous case reports indicated that naltrexone at the dosage of 50 mg/day successfully helped the patients to achieve abstinence. Studies have shown that naltrexone reduces the antidepressant effects of ketamine in treatment-resistant depression, indicating an overlap between the opioid system and ketamine's NMDA receptor activity."

Important to note that while ketamine can be used as a medicine in substance use disorder, people can sometimes become dependent with misuse, which may be addressed by naltrexone.

More like this

Spotlight: A long, strange trip: Ketamine treatment in psychiatry (Nutt, et al, 2025)

"...mystical experiences were strongly related to immediate and sustained psychiatric benefits at the group level and on an individual, session-by-session basis across the six doses, providing mechanistic support for ketamine-psychotherapy pairings."

Spotlight: Rapid-acting NMDA and GABAergic Modulators in Mood Disorders: From Synaptic Mechanisms to Clinical Practice (Serretti, 2025)

"Depression is increasingly conceptualized as a disorder of impaired synaptic plasticity and excitation-inhibition imbalance within corticolimbic circuits. Ketamine, brexanolone, zuranolone, offer complementary approaches to restore circuit function."

Spotlight: Personality profiles and trauma history in ketamine therapy for mood and anxiety disorders: A latent profile analysis of short-term outcomes (Gregoire, et al, 2025)

"Personality traits relate to baseline mental health severity but not short-term response to ketamine. Trauma history may predict greater benefit from treatment."

Spotlight: Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction (Palhas, et al, 2025)

"Serotonergic psychedelics & ketamine appear to share common cellular mechanisms. They both recruit glutamatergic neurons to stimulate BDNF-trKB signaling, promoting synaptogenesis via the mTOR pathway. These changes may explain their efficacy in depression, anxiety, PTSD, & addiction."

Spotlight: Modulation of functional network co-activation pattern dynamics following ketamine treatment in major depression (Taraku, et al, 2025)

"findings suggest ketamine modulates brain network dynamics which may normalize dynamic patterns seen in TRD at baseline toward patterns seen in controls. Changes in Salience Network state dynamics may correspond to improvements in ruminative symptoms following ketamine therapy."

Spotlight: Intermittent ketamine and neuromodulation treatment evoke synergistic antidepressant-relevant action (Brown, et al, 2025)

"The rapid response that can be observed following ketamine treatment has reconceptualized how pharmacotherapy can treat depression. One subanesthetic infusion can alleviate symptoms within hours; however, sustained relief also requires multiple doses. "
Mastodon Mastodon